In the last trading session, 1.89 million Beam Therapeutics Inc (NASDAQ:BEAM) shares changed hands as the company’s beta touched 1.93. With the company’s per share price at $24.52 changed hands at $0.29 or 1.20% during last session, the market valuation stood at $2.45B. BEAM’s last price was a discount, traded about -49.88% off its 52-week high of $36.75. The share price had its 52-week low at $20.84, which suggests the last value was 15.01% up since then. When we look at Beam Therapeutics Inc’s average trading volume, we note the 10-day average is 2.84 million shares, with the 3-month average coming to 1.52 million.
Analysts gave the Beam Therapeutics Inc (BEAM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.53. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended BEAM as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Beam Therapeutics Inc’s EPS for the current quarter is expected to be -1.17.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Instantly BEAM was in green as seen at the end of in last trading. With action -4.55%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -1.13%, with the 5-day performance at -4.55% in the red. However, in the 30-day time frame, Beam Therapeutics Inc (NASDAQ:BEAM) is -14.30% down. Looking at the short shares, we see there were 9.99 million shares sold at short interest cover period of 7.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 38, meaning bulls need an upside of 35.47% from its current market value. According to analyst projections, BEAM’s forecast low is 25 with 57 as the target high. To hit the forecast high, the stock’s price needs a -132.46% plunge from its current level, while the stock would need to soar -1.96% for it to hit the projected low.
Beam Therapeutics Inc (BEAM) estimates and forecasts
Year-over-year growth is forecast to reach 1.86% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 14.9M. 10 analysts are of the opinion that Beam Therapeutics Inc’s revenue for the current quarter will be 15.82M. The company’s revenue for the corresponding quarters a year ago was 7.41M and 11.77M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 101.12%. The estimates for the next quarter sales put growth at 34.37%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.88%. The 2025 estimates are for Beam Therapeutics Inc earnings to decrease by -5.18%, but the outlook for the next 5-year period is at -1.73% per year.
BEAM Dividends
Beam Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-24.
Beam Therapeutics Inc (NASDAQ:BEAM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.21% of Beam Therapeutics Inc shares while 79.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.04%. There are 79.07% institutions holding the Beam Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.6701% of the shares, roughly 7.9 million BEAM shares worth $185.11 million.
FARALLON CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.6135% or 7.91 million shares worth $185.4 million as of 2024-06-30.
